REFERENCES
1. American Diabetes Association Professional Practice Committee for Diabetes*. 9. Pharmacologic approaches to glycemic treatment: standards of care in Diabetes-2026. Diabetes Care. 2026;49:S183-215.
2. Ben Nasr M, Usuelli V, Dellepiane S, et al. Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule. Cell Metab. 2024;36:1302-19.e12.
3. Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139:2022-31.
4. Gitto M, Catapano F, Francone M, et al. GLP-1 receptor agonists and coronary plaques regression in diabetic patients after acute coronary syndromes. Acta Diabetol. 2026;63:179-91.
5. McGuire DK, Marx N, Mulvagh SL, et al. ; SOUL Study Group. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025;392:2001-12.
6. Solis-Herrera C, Kane MP, Triplitt C. Current understanding of sodium N-(8-[2-Hydroxylbenzoyl] Amino) caprylate (SNAC) as an absorption enhancer: the oral semaglutide experience. Clin Diabetes. 2024;42:74-86.
7. Frias JP, Hsia S, Eyde S, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023;402:472-83.
8. Pratt E, Ma X, Liu R, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Diabetes Obes Metab. 2023;25:2634-41.
9. Rosenstock J, Yabe D, Cox D, et al. ; ACHIEVE-3 Investigators. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026;407:1147-60.
10. Aroda VR, Aberle J, Bardtrum L, et al. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. Lancet. 2023;402:693-704.
11. Rossi G, Bucciarelli L, Mananguite CL, Giovarelli M, Fiorina P. Muscle loss and GLP-1R agonists use. Acta Diabetol. 2026;63:333-42.
12. Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis. Metabolism. 2025;164:156113.
